TREA

97664408 - XCELLIT

Follow

Information

  • Trademark
  • 97664408
  • Serial Number
    97664408
  • Registration Number
    7313860
  • Filing Date
    November 05, 2022
    2 years ago
  • Registration Date
    February 27, 2024
    10 months ago
  • Transaction Date
    February 27, 2024
    10 months ago
  • Status Date
    February 27, 2024
    10 months ago
  • Published for Opposition Date
    December 12, 2023
    a year ago
  • Location Date
    February 27, 2024
    10 months ago
  • Status Code
    700
  • Current Location
    PUBLICATION AND ISSUE SECTION
    Employee Name
    BERLIN, JUSTIN E
  • Attorney Name
    Alexandra MacKay
    Law Office Assigned Location Code
    N70
  • Owners
Information
Mark Drawing Code
5000
Mark Identification
XCELLIT
Case File Statements
  • DM0000: The mark consists of the stylized word "XCELLIT".
  • GS0091: recorded software used as medical monitoring and control tool, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded software as a medical device (SaMD), specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; recorded computer software for use in medical decision support systems specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment
  • CC0000: Color is not claimed as a feature of the mark.
  • GS0441: Medical services; medical and pharmaceutical evaluation of medical and pharmaceutical products to determine effectiveness and suitability for use in treatment of specific medical conditions; medical services, namely, cell therapy services; Medical services relating to the removal, treatment and processing of human cells
  • GS0101: Medical apparatus and instruments for use in apheresis, production of cell and gene therapies, testing, analysis, and quality assurance of cell and gene therapies, infusion of cell and gene therapies, and analysis of data gathered from the cell and gene therapy treatment; apparatus and instruments for cell analysis for medical use, namely, cancer and autoimmune disease treatment; medical apparatus in the nature of a system comprising an automated manufacturing device, reagents, software for the purpose of coordinating the treatment of patients, monitoring and conducting quality control on the testing of blood derived cells, supporting clinical decisions regarding the use of such cells for infusion and treatment, and the analysis of the results from such treatment
  • GS0421: Software as a service (SAAS) services featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; providing temporary use of nondownloadable, cloud-based software featuring software for medical monitoring and control specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information; software as a service (SAAS) services for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; providing temporary use of non-downloadable, cloud-based software featuring software for use in medical decision support systems, specifically, software that coordinates the treatment of patients, that monitors and controls manufacture, supply, workflow, and coordinates scheduling of delivery of chimerin antigen receptor T-cell therapy, that records patient status, treatment, and vitals, that gathers, stores, sends, and makes accessible patient data and treatment information, and that supports clinical decisions regarding the use of blood derived cells for infusion and treatment and the analysis of the results from such treatment; Providing information about the results of clinical trials for pharmaceutical products; scientific research in the nature of conducting clinical trials; Providing information about the results of clinical trials; evaluation pharmaceutical products in the nature of product quality testing; providing information regarding the product quality testing and clinical trials of pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; medical and pharmaceutical product quality testing; advisory and consultancy services in the field of medical and pharmaceutical product development
Case File Event Statements
  • 2/27/2024 - 10 months ago
    19 - NOTICE OF REGISTRATION CONFIRMATION EMAILED Type: NRCC
  • 2/27/2024 - 10 months ago
    18 - REGISTERED-PRINCIPAL REGISTER Type: R.PR
  • 12/12/2023 - a year ago
    17 - OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Type: NPUB
  • 12/12/2023 - a year ago
    16 - PUBLISHED FOR OPPOSITION Type: PUBO
  • 11/22/2023 - a year ago
    15 - NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Type: NONP
  • 11/6/2023 - a year ago
    14 - APPROVED FOR PUB - PRINCIPAL REGISTER Type: CNSA
  • 11/6/2023 - a year ago
    13 - ASSIGNED TO EXAMINER Type: DOCK
  • 9/18/2023 - a year ago
    12 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME
  • 9/18/2023 - a year ago
    11 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA
  • 9/17/2023 - a year ago
    10 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA
  • 8/24/2023 - a year ago
    9 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN
  • 8/24/2023 - a year ago
    8 - NON-FINAL ACTION E-MAILED Type: GNRT
  • 8/24/2023 - a year ago
    7 - NON-FINAL ACTION WRITTEN Type: CNRT
  • 8/21/2023 - a year ago
    6 - ASSIGNED TO EXAMINER Type: DOCK
  • 1/19/2023 - a year ago
    5 - PRELIMINARY/VOLUNTARY AMENDMENT - ENTERED Type: AMPX
  • 1/19/2023 - a year ago
    4 - ASSIGNED TO LIE Type: ALIE
  • 11/19/2022 - 2 years ago
    3 - TEAS VOLUNTARY AMENDMENT RECEIVED Type: PARI
  • 11/23/2022 - 2 years ago
    2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS
  • 11/9/2022 - 2 years ago
    1 - NEW APPLICATION ENTERED Type: NWAP